References
Alkondon M, Pereira EF, Todd SW, Randall WR, Lane MV, Albuquerque EX (2015) Functional G-protein-coupled receptor 35 is expressed by neurons in the CA1 field of the hippocampus. Biochem Pharmacol. 93:506-518. Banerjee J, Alkondon M, Albuquerque EX (2012) Kynurenic acid inhibits glutamatergic transmission to CA1 pyramidal neurons via a7 nAChR-dependent and -independent mechanisms. Biochem Pharmacol. 84:1078–1087. Banerjee J, Banerjee Dixit A, Srivastava A, Ramanujam B, Kakkar A, Sarkar C, Tripathi M, Chandra PS (2017) Altered glutamatergic tone reveals two distinct resting state networks at the cellular level in hippocampal sclerosis. Sci Rep. 7:319 Banerjee J, Banerjee Dixit A, Tripathi M, Sarkar C, Gupta YK, Chandra PS (2015) Enhanced endogenous activation of NMDA receptors in pyramidal neurons of hippocampal tissues from patients with mesial temporal lobe epilepsy: A mechanism of hyper excitation. Epilepsy Res. 117:11-16. Banerjee J, Dey S, Banerjee Dixit A, Tripathi M, Doddamani R, Sharma MC, Chandra PS (2020) α7 nicotinic receptors contributes to glutamatergic activity in the hippocampus of patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE‑HS). J Neural Transm. 127:1441–1446. Cabo R, Kozik K, Milanowski M, Hernes S, Slettan A, Haugen M, Ye S, Blomhoff R, Mansoor MA (2014) A simple high-performance liquid chromatography (HPLC) method for the measurement of pyridoxal-5-phosphate and 4-pyridoxic acid in human plasma. Clin Chim Acta. 433:150-156 Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteriet M, Moroni F (2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 13:2141-2147. de Moura, Tirapelli DP, Neder L, Saggioro FP, Sakamoto AC, Velasco TR, Panepucci RA, Leite JP, Assirati Júnior JA, Colli BO, Carlotti Júnior CG (2012) Amygdala gene expression of NMDA and GABA(A) receptors in patients with mesial temporal lobe epilepsy. Hippocampus. 22:92-97 DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 115:89-97. Engel J (2001) Mesial temporal lobe epilepsy: what have we learned? Neuroscientist. 7:340-352. Engel, J (2001) Mesial temporal lobe epilepsy: what have we learned? Neuroscientist. 7:340-352. Guillemin G, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 78:842–853. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 21:7463-7473. Ito M, Seki T, Takuma, Y (2000) Current therapy of West syndrome in Japan. J Child. Neurol. 15:424–428. Jaeger B, Abeling NG, Salomons GS, Struys EA, Simas-Mendes M, Geukers VG, Poll-The BT (2016) Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation. Mol Genet Metab Rep. 10:60-63. Jallon P, Loiseau P, Loiseau J (2001) Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Coordination Active du Réseau Observatoire Longitudinal de l’ Epilepsie. Epilepsia. 42:464-475. Jin SH, Jeong W, Chung CK (2015) Mesial temporal lobe epilepsy with hippocampal sclerosis is a network disorder with altered cortical hubs. Epilepsia. 56:772–779. Josephson CB, Dykeman J, Fiest KM, Liu X, Sadler RM, Jette N, Wiebe S (2013) Systematic review and meta-analysis of standard vs selective temporal lobe epilepsy surgery. Neurology. 80:1669-1676. Kakkar A, Biswas A, Goyal N, Suri V, Sharma MC, Gupta D, Julka PK, Sarkar C (2016) The Expression of Cyclin D1, VEGF, EZH2, and H3K27me3 in atypical teratoid/rhabdoid tumors of the CNS: a possible role in targeted therapy. Appl Immunohistochem Mol Morphol. 24:729-737. Kamiński RM, Zielińska E, Dekundy A, van Luijtelaar G, Turski W (2003) Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol J Pharmacol. 55:741-746. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with NMDA receptors: characterisation and identification of a new class of antagonist. J Neurochem. 52:1319–1328. Kuo MF, Wang HS (2002) Pyridoxal phosphate responsive epilepsy, with resistance to pyridoxine. Pediatr Neurol. 26:146–147. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Moshé SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069-77. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402-408. Maciejak P. Szyndler J, Turzyńska D, Sobolewska A, Taracha E, Skórzewska A, Lehner M, Bidziński A, Płaźnik A (2008) Time course of changes in the concentration of kynurenic acid in the brain of pentylenetetrazol-kindled rats. Brain Res Bull. 78:299-305. Moroni F, Cozzi A, Sili M, Mannaioni G (2012) Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 119:133–139. Musayev FN, Di Salvo ML, Saavedra M, Contestabile R, Ghatke M, Haynes A, Schirch V, Safo MK (2009) Molecular basis of reduced pyridoxine 5′-phosphate oxidase catalytic activity in neonatal epileptic encephalopathy disorder. J Biol Chem. 284:30949–30956. Nürnberger S, Lindner C, Maier J, Strohmeier K, Wurzer C, Slezak P, Suessner S, Holnthoner W, Redl H, Wolbank S, Priglinger E (2019) Adipose-tissue-derived therapeutic cells in their natural environment as an autologous cell therapy strategy: the microtissue-stromal vascular fraction. Eur Cell Mater. 37:113-133 Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM (1997) Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 283:1264–1275 Perkins M, Stone T (1984) Actions of excitatory amino acids and kynurenic acid in the primate hippocampus: A preliminary study. Neurosci Lett. 52:335-340. Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R (2011) Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology. 36:2357-2367. Potter M, Elmer G, Bergeron R, Albuquerque E, Guidetti P, Wu H, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 35:1734-1742. Rassoulpour A, Wu HQ, Ferré S, Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 93:762–765. Roy S, Sharma HP, Nag TC, Velpandian T, Upadhyay AD, Mathur R, Jain S (2014) BDNF mediated activity dependent maturation of visual Wulst following prenatal repetitive auditory stimulation at a critical developmental period in domestic chicks (Gallus domesticus). Brain Res Bull. 109:99-108. Scharfman HE (2007) The neurobiology of epilepsy. Curr Neurol Neurosci. Rep. 7:348-354. Schwarcz R, Bruno J, Muchowski P, Wu H (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 13:465-477. Szyndler J, Maciejak P, Turzyńska D, Sobolewska A, Walkowiak J, Płaźnik A (2012) The effects of electrical hippocampal kindling of seizures on amino acids and kynurenic acid concentrations in brain structures. J Neural Transm. 119:141-149. Tripathi M, Ray S, Chandra PS (2016) Presurgical evaluation for drug refractory epilepsy. Int J Surg. 36:405-410. Turski WA, Gramsbergen JB, Traitler H, Schwarcz R (1989) Rat Brain Slices Produce and Liberate Kynurenic Acid upon Exposure to L-Kynurenine. J Neurochem. 52:1629-1636. Watanabe K (1995) Medical treatment of West syndrome in Japan. J Child Neurol. 10:143–147. Wu H, Turski W, Ungerstedt U, Sahwarcz R (1991) Systemic Kainic Acid Administration in Rats: Effects on Kynurenic Acid Production in Vitro and in Vivo. Exp Neurol. 113:47-52. Xiao LD, Luo XB, Pi LG, Tang AG (2008) Simultaneous determination of kynurenine and kynurenic acid concentrations in human serum by HPLC with dual wavelengths fluorescence detection. Clin Chim Acta. 395:178-180 Yamamoto H, Murakami H, Horiguchi K, Egawa B (1995) Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev. 17:327-329. Yamamoto H, Shindo I, Egawa B, Horiguchi K (1994) Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms. Pediatr Neurol. 10:9-12.
Table 1. Characteristics of PSCs (frequency, amplitude, rise time, decay time constant) recorded from pyramidal neurons in non-seizure controls and hippocampal samples obtained from patients with MTLE-HS.